Related content

The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer’s disease

By Melchor Jerry   Pawlak Robert   Chen Zulin   Strickland Sidney  

Journal of Molecular Neuroscience, Vol. 20, Iss. 3, 2003-08 ,pp. : 287-289

Humana Press, Inc

Access to resources Recommend Favorite

Antioxidant treatment in alzheimer’s disease: Current state

By Gilgun-Sherki Yossi   Melamed Eldad   Offen Daniel  

Journal of Molecular Neuroscience, Vol. 21, Iss. 1, 2003-09 ,pp. : 1-11

Humana Press, Inc

Access to resources Recommend Favorite

Immunological approach for the treatment of Alzheimer’s disease

By Solomon Beka  

Journal of Molecular Neuroscience, Vol. 20, Iss. 3, 2003-08 ,pp. : 283-286

Humana Press, Inc

Access to resources Recommend Favorite

Biological markers and the treatment of Alzheimer’s Disease

By Galasko Douglas  

Journal of Molecular Neuroscience, Vol. 17, Iss. 2, 2001-10 ,pp. : 119-125

Humana Press, Inc

Access to resources Recommend Favorite

Somatic comorbidities and Alzheimer’s disease treatment

By Clodomiro Alessandra   Gareri Pietro   Puccio Gianfranco   Frangipane Francesca   Lacava Roberto   Castagna Alberto   Manfredi Valeria   Colao Rosanna   Bruni Amalia  

Neurological Sciences, Vol. 34, Iss. 9, 2013-09 ,pp. : 1581-1589

Springer Publishing Company

Access to resources Recommend Favorite